A Phase I Clinical Trial to Evaluate the Tolerability and the Pharmacokinetics of CKD-386 With Co-administration of D013, D326, and D337 in Healthy Adult Volunteers
Latest Information Update: 17 Jan 2023
At a glance
- Drugs CKD 386 (Primary)
- Indications Dyslipidaemias; Hypertension
- Focus Pharmacokinetics
- Sponsors Chong Kun Dang
Most Recent Events
- 17 Jan 2023 Last checked against ClinicalTrials.gov: US National Institutes of Health record.
- 10 Jan 2023 Status changed from not yet recruiting to completed.
- 26 Sep 2022 New trial record